Literature DB >> 29648512

Malignant ureteric obstruction decompression: how much gain for how much pain? A narrative review.

Joanna Prentice1, Tarik Amer1,2, Ali Tasleem3, Omar Aboumarzouk1,2,4.   

Abstract

Over the last thirty years, the management of Malignant Ureteric Obstruction (MUO) has evolved from a single disciplinary decision to a multi-disciplinary approach. Careful consideration must be given to the risks and benefits of decompression of hydronephrosis for an individual patient. There is a lack of consensus of opinion as well as strong evidence to support the decision process. Outcomes that were identified amongst patients undergoing treatment for MUO included prognosis, quality of life (QOL), complications, morbidity and prognostication tools. A total of 63 papers were included. Median survival was 6.4 months in the 53 papers that stated this outcome. Significant predictors to poor outcomes included low serum albumin, hyponatremia, the number of malignancy related events, and performance status of 2 or worse on the European cooperative cancer group. We propose a multi-centre review of outcomes to enable evidence-based consultations for patients and their families.

Entities:  

Keywords:  Clinical; end of life decisions (palliative care); oncology; palliative care; urological cancer; urology

Mesh:

Year:  2018        PMID: 29648512      PMCID: PMC5900840          DOI: 10.1177/0141076818766725

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  27 in total

1.  The role of percutaneous nephrostomy in malignant ureteric obstruction.

Authors:  J R Wilson; G H Urwin; M J Stower
Journal:  Ann R Coll Surg Engl       Date:  2005-01       Impact factor: 1.891

2.  Survival and quality of life after percutaneous nephrostomy for malignant ureteric obstruction in patients with terminal cervical cancer.

Authors:  C Emmert; J Rassler; U Köhler
Journal:  Arch Gynecol Obstet       Date:  1997       Impact factor: 2.344

3.  Impact of palliative urinary diversion by percutaneous nephrostomy drainage and ureteral stenting among patients with advanced cervical cancer and obstructive uropathy: a prospective cohort.

Authors:  Marie Carmela M Lapitan; Brian S Buckley
Journal:  J Obstet Gynaecol Res       Date:  2011-04-12       Impact factor: 1.730

4.  A qualitative study exploring male cancer patients' experiences with percutaneous nephrostomy.

Authors:  Lene Hyldgaard Bigum; Marlène Elisabeth Spielmann; Gitte Juhl; Annlise Rasmussen
Journal:  Scand J Urol       Date:  2014-12-01       Impact factor: 1.612

5.  Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy.

Authors:  E Radecka; M Magnusson; A Magnusson
Journal:  Acta Radiol       Date:  2006-04       Impact factor: 1.990

6.  Malignant ureteral obstruction: outcomes after intervention. Have things changed?

Authors:  Lih-Ming Wong; Laurence K Cleeve; Alvin D Milner; Alexander G Pitman
Journal:  J Urol       Date:  2007-05-17       Impact factor: 7.450

7.  The role of percutaneous nephrostomy in gynecologic oncology.

Authors:  W J Mann; K D Hatch; P T Taylor; E M Partridge; J W Orr; H M Shingleton
Journal:  Gynecol Oncol       Date:  1983-12       Impact factor: 5.482

8.  Palliative urinary diversion for pelvic malignancy.

Authors:  E N Brin; M Schiff; R M Weiss
Journal:  J Urol       Date:  1975-05       Impact factor: 7.450

9.  Percutaneous nephrostomy catheter use in gynecologic malignancy: M.D. Anderson Hospital experience.

Authors:  B S Dudley; D M Gershenson; J J Kavanagh; L J Copeland; C H Carrasco; F N Rutledge
Journal:  Gynecol Oncol       Date:  1986-07       Impact factor: 5.482

10.  Prognostic marker for patients with malignant ureter obstruction.

Authors:  Takeshi Azuma; Yasushi Nagase; Masaya Oshi
Journal:  Clin Genitourin Cancer       Date:  2013-06-17       Impact factor: 2.872

View more
  1 in total

1.  Percutaneous nephrostomy in obstructing pelvic malignancy does not facilitate further oncological treatment.

Authors:  Samuel Stephen Folkard; Srijit Banerjee; Richard Menzies-Wilson; Joseph Reason; Evangelos Psallidas; Elliot Clissold; Ahmad Al-Mushatat; Saurabh Chaudhri; James Stephen Arthur Green
Journal:  Int Urol Nephrol       Date:  2020-04-22       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.